Functional interaction of melatonin receptors and D1 dopamine receptors in cultured chick retinal neurons.
The possible interaction of melatonin receptors and D1 dopamine receptors was investigated in neural cells prepared from embryonic day 8 chick retinas and cultured for 6 d. Dopamine stimulated cAMP accumulation in cultured retinal cells. This effect of dopamine was antagonized by addition of dopamine receptor antagonists (haloperidol and SCH23390) or melatonin receptor agonists (melatonin, 2-iodomelatonin, and 6-chloromelatonin). The inhibition of dopamine-stimulated cAMP accumulation by melatonin was concentration dependent, with half-maximal inhibition at approximately 160 pM. Melatonin inhibited the effect of dopamine at all dopamine concentrations, suppressing the maximal response to the neurotransmitter by approximately 70%. Melatonin also inhibited the stimulation of cAMP accumulation by SKF 82958, a selective D1 dopamine receptor agonist. Pretreatment of cultures with pertussis toxin had no significant effect on dopamine-stimulated cAMP accumulation, but inhibited the response to melatonin. In contrast to its effect on cAMP accumulation, melatonin had no effect on dopamine-stimulated inositol phosphate accumulation. These results suggest that melatonin receptors are coupled to dopamine receptor-regulated adenylate cyclase via an inhibitory G protein, and demonstrate another mechanism, in addition to inhibition of dopamine release, through which melatonin can modulate dopaminergic neurotransmission.
Iuvone
P M
PM
Department of Pharmacology, Emory University School of Medicine, Atlanta, Georgia 30322-3090.
Gan
J
J
D015056:1-Methyl-3-isobutylxanthine / Q000494:pharmacology; D037361:Adenylate Cyclase Toxin; D000818:Animals; D001552:Benzazepines / Q000494:pharmacology; D002478:Cells, Cultured; D002642:Chick Embryo; D000242:Cyclic AMP / Q000378:metabolism; D019204:GTP-Binding Proteins / Q000378:metabolism; D006220:Haloperidol / Q000494:pharmacology; D007295:Inositol Phosphates / Q000378:metabolism; D008550:Melatonin / Q000031:analogs & derivatives / Q000494:pharmacology; D008959:Models, Neurological; D009474:Neurons / Q000502:physiology*; D037342:Pertussis Toxin; D011956:Receptors, Cell Surface / Q000187:drug effects / Q000502:physiology*; D017447:Receptors, Dopamine D1 / Q000187:drug effects / Q000502:physiology*; D044094:Receptors, Melatonin; D012160:Retina / Q000196:embryology; D015398:Signal Transduction / Q000187:drug effects / Q000502:physiology; D009435:Synaptic Transmission / Q000187:drug effects; D010566:Virulence Factors, Bordetella / Q000494:pharmacology
D037361:Adenylate Cyclase Toxin; D001552:Benzazepines; D007295:Inositol Phosphates; D011956:Receptors, Cell Surface; D017447:Receptors, Dopamine D1; D044094:Receptors, Melatonin; D010566:Virulence Factors, Bordetella; C024100:6-chloromelatonin; C071262:SK&F 82958; C044556:2-iodomelatonin; D000242:Cyclic AMP; D037342:Pertussis Toxin; D019204:GTP-Binding Proteins; D006220:Haloperidol; D008550:Melatonin; D015056:1-Methyl-3-isobutylxanthine